Multiple Sclerosis Drugs and Treatment Market Dynamics, Segm...| MENAFN.COM

Sunday, 16 January 2022 10:13 GMT

Multiple Sclerosis Drugs and Treatment Market Dynamics, Segments and Supply Demand Forecast to 2027


(MENAFN- America News Hour)

According to Research Nester,  Multiple Sclerosis Drugs and Treatment Market in North America region is anticipated to witness largest share in the market on account of presence of highly advanced medical facilities along with large number of research institutions in the region.

Multiple Sclerosis Drugs and Treatment Market: Global Demand Analysis & Opportunity Outlook 2027 , which delivers detailed overview of the global multiple sclerosis drugs and treatment market in terms of market segmentation by drug, by route of administration, by distribution channel and by region.

Multiple sclerosis is an autoimmune disease that affects the central nervous system (CNS) of the body that mainly consists of the brain and spinal cord. It is a chronic health disorder that leads to the damage of nerves, thereby disrupting the communication between the brain and other parts of the body. The market for multiple sclerosis drugs and treatment is anticipated to grow at a significant CAGR of about 6% during the forecast period, i.e., 2019-2027. The market is segmented by drug, by route of administration, by distribution channel and by region. On the basis of drug, the market is further segmented into interferons, immunomodulators and immunosuppressants, out of which, the segment for immunomodulatory drugs is estimated to hold a significantly large share in the market during the forecast period. This can be attributed to the development of new methods of treatment for multiple sclerosis that are immunomodulatory in nature.

Get a PDF Sample for more detailed market insights:

The market in North America region is anticipated to witness largest share in the market on account of presence of highly advanced medical facilities along with large number of research institutions in the region. Additionally, the high prevalence of multiple sclerosis is another factor contributing towards the market growth. Further, the market in Europe is estimated to hold the second highest share as a result of growing demand for effective therapeutic drugs for the treatment of multiple sclerosis.

Rising Prevalence of Multiple Sclerosis to Boost the Market Growth

As per a journal published by the Lancet Neurology, there were 2,221,188 cases of multiple sclerosis prevalent around the world in 2016. The age-standardized prevalence of this disorder was higher than 120 cases per 100,000 people in North America. On the other hand, it was moderate in some European countries with 60 to 120 cases per 100,000 population and lowest in North Africa, Middle East and Latin America with less than 60 cases per 100,000 people in every region. The increasing prevalence of multiple sclerosis raises the demand for improved treatment methods for the disorder. This is estimated to become a factor responsible for the market growth. On the other hand, the strict government policies regarding the approval of drugs is anticipated to hinder the market growth.

Market Segment as follows: By Region / Countries

North America (U.S. & Canada), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa).

Access Full Report, here:

This report also provides the existing competitive scenario of some of the key players of the global multiple sclerosis drugs and treatment market which includes company profiling of Bayer AG (BAYN), Novartis AG (NOVN), Biogen (BIIB), Genzyme Corporation, F. Hoffmann-La Roche, Teva Pharmaceutical Industries Ltd., Pfizer Inc. (PFE), Merck KGaA (MRK), AbbVie Inc. and Opexa Therapeutics, Inc. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments.

About Research Nester

Research Nester is a one-stop service provider with a client base in more than 50 countries, leading in strategic market research and consulting with an unbiased and unparalleled approach towards helping global industrial players, conglomerates and executives for their future investment while avoiding forthcoming uncertainties. With an out-of-the-box mindset to produce statistical and analytical market research reports, we provide strategic consulting so that our clients can make wise business decisions with clarity while strategizing and planning for their forthcoming needs and succeed in achieving their future endeavors. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds.

Contact for more Info:

AJ Daniel

Email:

U.S. Phone: +1 646 586 9123

U.K. Phone: +44 203 608 5919

Research Nester

Research Nester is a one-stop service provider, leading in strategic market research and consulting with an unbiased and unparalleled approach towards helping global industrial players, conglomerates and executives to make wise decisions for their future investment and expansion by providing them qualitative market insights and strategies while avoiding future uncertainties. We believe in honesty and sheer hard work that we trust is reflected in our work ethics. Our vision is not just limited to gain the trust of our clients but also to be equally respected by our employees and being appreciated by the competitors.

MENAFN14012022004545010068ID1103538613


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.